Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $24.3700 (-2.21%) ($24.3100 - $25.7900) on Fri. Mar. 2, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.29% (three month average) | RSI | 20 | Latest Price | $24.3700(-2.21%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -1.3% a day on average for past five trading days. | Weekly Trend | ADMS declines -14.8% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(24%) IBB(22%) ARKK(18%) IWM(18%) IWO(18%) | Factors Impacting ADMS price | ADMS will decline at least -2.145% in a week (0% probabilities). VIXM(-12%) UNG(-10%) BNDX(-9%) UUP(-7%) TLT(-7%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.145% (StdDev 4.29%) | Hourly BBV | 0 () | Intraday Trend | -0.8% | | | |
|
1 - 5 Day Possible Target | $-0.06(-100.25%) | Resistance Level | $30.49 | 5 Day Moving Average | $24.91(-2.17%) | 10 Day Moving Average | $26.42(-7.76%) | 20 Day Moving Average | $30.49(-20.07%) | To recent high | -42.9% | To recent low | 0% | Market Cap | $689m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |